|Table of Contents|

Inhibitory effect of protein arginine methyltransferase 1 inhibitor DB75 on bladder cancer T24 cells(PDF)

Chinese Journal of Applied & Environmental Biology[ISSN:1006-687X/CN:51-1482/Q]

Issue:
2015 01
Page:
57-60
Research Field:
Articles
Publishing date:

Info

Title:
Inhibitory effect of protein arginine methyltransferase 1 inhibitor DB75 on bladder cancer T24 cells
Author(s):
ZENG Zhongqiu MA Yuling PEI Zhe CHEN Yuwen WANG Jing TANG Yaxiong
Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu 610041, China
Keywords:
bladder cancer PRMT1 DB75 apoptosis
CLC:
R965 : R979.1
PACS:
DOI:
10.3724/SP.J.1145.2014.09036
DocumentCode:

Abstract:
Protein arginine methyltransferase 1 (PRMT1), as a newly discovered epigenetic modified enzyme, is overexpressed in many cancers including bladder cancer and plays a crucial role in malignant transformation. Therefore, PRMT1 may be a novel valuable therapeutic target for cancer chemoprevention. In our study, DB75 was identified as a PRMT1 inhibitor by using the pharmacophore-based virtual screening system, and the antitumor potential and molecular mechanism of DB75 were further evaluated in vitro. The experimental results showed that DB75 signi?cantly suppressed the proliferation of bladder cancer T24 cells in a dose-dependent manner, with the IC50 value as 2.2 μmol/L after 48 h exposure to DB75. In addition, DB75 induced apoptosis in T24 cells. Altogether, DB75 could activate Caspase-3 and PARP activity, and lead to marked apoptotic effect on bladder cancer T24 cells. Together, these ?ndings suggested that DB75 may be a promising epigenetic lead compound for prevention and treatment of bladder cancer.

References

1 Hojfeldt JW, Agger K, Helin K. Histone lysine demethylases as targets for anticancer therapy [J]. Nat Rev Drug Discov, 2013, 12 (12): 917-930
2 Mair B, Kubicek S, Nijman SM. Exploiting epigenetic vulnerabilities for cancer therapeutics [J]. Trends Pharmacol Sci, 2014, 35 (3): 136-145
3 Bedford MT, Clarke SG. Protein arginine methylation in mammals: who, what, and why [J]. Mol Cell, 2009, 33 (1): 1-13
4 Cheung N, Chan LC, Thompson A, Cleary ML, So CW. Protein arginine-methyltransferase-dependent oncogenesis [J]. Nat Cell Biol, 2007, 9 (10): 1208-1215
5 Mathioudaki K, Scorilas A, Ardavanis A, Lymberi P, Tsiambas E, Devetzi M, Apostolaki A, Talieri M. Clinical evaluation of PRMT1 gene expression in breast cancer [J]. Tumour Biol, 2011, 32 (3): 575-582
6 Wang S, Tan X, Yang B, Yin B, Yuan J, Qiang B, Peng X. The role of protein arginine-methyltransferase 1 in gliomagenesis [J]. BMB Rep, 2012, 45 (8): 470-475
7 Mathioudaki K, Papadokostopoulou A, Scorilas A, Xynopoulos D, Agnanti N, Talieri M. The PRMT1 gene expression pattern in colon cancer [J]. Br J Cancer, 2008, 99 (12): 2094-2099
8 Dudziec E, Goepel JR, Catto JW. Global epigenetic profiling in bladder cancer [J]. Epigenomics, 2011, 3 (1): 35-45
9 Yoshimatsu M, Toyokawa G, Hayami S, Unoki M, Tsunoda T, Field HI, Kelly JD, Neal DE, Maehara Y, Ponder BA, Nakamura Y, Hamamoto R. Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers [J]. Int J Cancer, 2011, 128 (3): 562-573
10 Wang J, Chen L, Sinha SH, Liang Z, Chai H, Muniyan S, Chou YW, Yang C, Yan L, Feng Y, Li KK, Lin MF, Jiang H, Zheng YG, Luo C. Pharmacophore-based virtual screening and biological evaluation of small molecule inhibitors for protein arginine methylation [J]. J Med Chem, 2012, 55 (18): 7978-7987
11 Yan L, Yan C, Qian K, Su H, Kofsky-Wofford SA, Lee WC, Zhao X, Ho MC. Ivanov I, Zheng YG. Diamidine compounds for selective inhibition of protein arginine methyltransferase 1 [J]. J Med Chem, 2014, 57 (6): 2611-2622
12 王晶, 安君霞, 朱启彧, 马玉玲, 裴哲, 魏枭, 孙健, 唐亚雄. 卡瓦胡椒素B对人非小细胞肺癌A549细胞的抑制作用[J]. 应用与环境生物学报, 2012, 18 (5): 740-744 [Wang J, An JX, Zhu QY, Ma YL, Pei Z, Wei X, Sun J, Tang YX. Inhibitory effect of Flavokawain B on human non-small cell lung cancer A549 cells [J]. Chin J Appl Environ Biol, 2012, 18 (5): 740-744]
13 Chen QW, Zhu XY, Li YY, Meng ZQ. Epigenetic regulation and cancer (review) [J]. Oncol Rep, 2014, 31 (2): 523-532
14 Mund C, Lyko F. Epigenetic cancer therapy: proof of concept and remaining challenges [J]. Bioessays, 2010, 32 (11): 949-957
15 Luo C, Xie P, Marmorstein R. Identification of BRAF inhibitors through in silico screening [J]. J Med Chem, 2008, 51 (19): 6121-6127
16 Chen Z, Tian G, Wang Z, Jiang H, Shen J, Zhu W. Multiple pharmacophore models combined with molecular docking: a reliable way for efficiently identifying novel PDE4 inhibitors with high structural diversity [J]. J Chem Inf Model, 2010, 50 (4): 615-625

Memo

Memo:
-
Last Update: 2015-02-15